Get the Stockscreener App
85.00
17.83%
-18.44
After Hours:
86.09
1.09
+1.28%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $85.00, with a volume of 53.47M.
It is down -17.83% in the last 24 hours and down -19.26% over the past month.
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$103.44
Open:
$82.72
24h Volume:
53.47M
Relative Volume:
8.95
Market Cap:
$377.54B
Revenue:
$39.36B
Net Income/Loss:
$13.79B
P/E Ratio:
35.30
EPS:
2.4077
Net Cash Flow:
$9.83B
1W Performance:
-20.52%
1M Performance:
-19.26%
6M Performance:
-39.71%
1Y Performance:
-16.10%
1-Day Range:
$81.50
$86.53
1-Week Range:
$81.50
$109.88
52-Week Range:
$81.50
$148.15
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally - The Motley Fool
Novo Nordisk: Shares Look Fairly Valued After CagriSema Disappointment - Morningstar
European Equities Traded in the US as American Depositary Fall in Wednesday Trading - MSN
Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue - Barron's
Why Novo Nordisk A/S (NVO) Is the Best ADR Stock to Invest in? - Insider Monkey
12 Best ADR Stocks To Invest In According to Analysts - Insider Monkey
NVO Stock Quote Price and Forecast - CNN
European Equities Traded in the US as American Depositary Decline in Tuesday Trading - MSN
Novo Nordisk ADR (NYSE: NVO) Could Fell Another -55.9% - Stocks Register
Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - The Manila Times
10 Biggest Biotechnology Companies - Investopedia
Biopharma Stock Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges - Morningstar
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View - Yahoo Finance
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading - MSN
Novo Nordisk ADR earnings beat by $5.24, revenue topped estimates - Investing.com Australia
Thanks To Wall Street, Novo Nordisk Stock Is Now A Buy - Barchart
Globalization Isn’t in Decline. Here’s Why That Matters for Investors - Morningstar
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
India Subcutaneous Drug Delivery Devices Market Size & Outlook, 2030 - Grand View Research
Why this money manager sees FirstService, Novo Nordisk and Microsoft as good long-term holdings - The Globe and Mail
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
1.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):